Kornimate/medical-research-clean huggingface dataset:
strip meniscometry in dry eye evaluation

Conditions: Dry Eye; Dry Eye Disease

Summary: strip meniscometry is a relatively new method for evaluating the tear meniscus. the aim of the study is to evaluate the possible effect of cataract surgery on ocular surface disease and to assess the possible benefit of strip meniscometry in the preoperative and postoperative evaluation of patients.

cataract surgery is one of the most successful anterior segment surgeries and usually results in excellent postoperative visual acuity. however, some patients may experience symptoms of dry eye disease after a successful procedure, most commonly a foreign body sensation in the eye, intermittent pain, and blurred vision. these problems then interfere with normal daily activities and also reduce the patient's satisfaction with the surgery. the new method for tear film examination strip meniscometry (sm) appears to be a suitable alternative to the schirmer test. sm values correlate with oxford score (fluorescein staining), tear break up time test or measurement of meniscus height using anterior segment optical coherence tomography. it is a minimally invasive and rapid examination method that measures the volume of the aqueous component of the tear film. the aim of this study is to evaluate the possible influence of cataract surgery on the development of iatrogenic osd and to assess the contribution of a new diagnostic method, sm, for the evaluation of osd before and after cataract surgery.

Eligibility criteria:
inclusion criteria: * age over 18 years * performing of pre-operative examination before cataract surgery * signed informed consent exclusion criteria: * use of antiglaucoma drugs * chronic blepharitis * previous viral keratitis * previous keratoplasty or laser refractive surgery * known systemic disease causing changes on ocular surface (diabetes mellitus, connective tissue disease) * use of medication causing changes on ocular surface (antidepressant, beta blockers)
tcr-t cells for the treatment ny-eso-1-positive advanced solid tumors

Conditions: Solid Tumors

Summary: new york esophageal squamous cell carcinoma 1 (ny-eso-1) is a cancer-testis antigen (cta) which is expressed in various tumors. after selected the high affinity tcr gene to ny-eso-1, the researchers insert genes into the cell that expressing a kind of protein that targeting ny-eso-1. then the engineered cells are re-infused in the patients with tumors for curing the tumor patient or prolonging life.

this is a single-center, open-label, phase i clinical study of tcr-t cells for the treatment of the recurrent/metastatic solid tumors patients who had failed standard therapy. tcr-t cells are expanded from peripheral blood, and after ex vivo modification, and extensive expansion, are reinfused to patients after non-myeloablative lymphocyte-depleting preparative regimen. the primary purpose of this study is to evaluate the safety and tolerability of tcr-t cells in patients with recurrent/metastatic solid tumors. the second purpose of this study is to preliminarily explore the effectiveness of tcr-t cells in patients with recurrent/metastatic solid tumors. eligibility: adults aging 18-70 who were failed to standard treatment or have no standard treatment with recurrent/metastatic solid tumors.

Eligibility criteria:
inclusion criteria: 1. have the willingness to communicate with investigator, be able to understand and follow the trail requirements, and voluntarily to participate in the trail; 2. 18 \~70 years old (gender is not limited;) 3. the expected survival period is at least 3 months; 4. ecog score of 0-1; 5. patients with recurrent or metastatic solid tumors confirmed by histopathology; 6. subjects who failed standard treatment in the past or have no standard treatment currently tor who are judged by the investigator to be unsuitable for current standard treatment for other reasons, and the objective imaging assessment is disease progression; 7. according to recist 1.1 standard, there is at least one measurable target lesion for efficacy evaluation; 8. ny-eso-1 positive; 9. hla type is hla-a2 (except hla-a\*0203); exclusion criteria: 1. female subjects who are pregnant or breastfeeding, or have a positive blood pregnancy test at baseline; 2. subjects who have had severe allergic reactions to any drug or its components in this trial in the past; 3. subjects who have received any investigational drug within 28 days before the infusion of til cells, or participated in another clinical study at the same time; 4. subjects who have other known history of malignant tumors in the past 5 years, except for localized tumors that have been cured, including in situ cervical carcinoma, basal cell carcinoma of the skin, and in situ prostate carcinoma; 5. patients who have received adoptive cell therapy in the past; 6. according to the judgment of the investigator, the condition of the subject is not suitable for this trial.
the nmfact caries index

Conditions: Dental Caries

Summary: the nmfact is a new caries index to overcome the drawbacks of dmf cries index the ''n'' is for non carious lesion, the ''m''for missed teeth,the ''f''for filled teeth,the''c''for carious teeth,the ''a''for alignment and the ''t''for dental trauma. each problem will be scored from 0(normal).

the new caries index will be used to record the dental problem . the validation will be recorded against the gold standard dmf index

Eligibility criteria:
inclusion criteria: * any patient suffering form dental problem exclusion criteria: * edentulous patient children adolescents
the effect of deliberate hypotension on qtc, tp-e intervals and heart rate variability

Conditions: Mandibular Prognathism; Mandibular Retrognathism

Summary: deliberate hypotension is defined as lowering the systolic blood pressure to 80-90mmhg, or the mean blood pressure to 50-65mmhg. this technique is usually employed for operations that have a high risk of intraoperative hemorrhage, such as orthognathic surgery. several different regimens are used to lower the patient's blood pressure, such as vasodilators, autonomic nervous system inhibitors, opioids and inhalation anesthetics. however, the effects that these agents have on the qtc and tp-e intervals during deliberate hypotension is not known. virtually every kind of anesthetic is reported to have some effect on the qtc and tp-e intervals. because orthognathic surgery usually takes 3-4 hours to complete, the amount of anesthetics and drugs used to maintain low blood pressure is not small. therefore, the effect that these agents may have on the qtc and tp-e intervals may not be negligible. the investigators of the present study found that the high dose of commonly used hypotensive agents tend to prolong these variabilities to some extent. this study will be able to provide insight as to which hypotensive anesthesia regimen has the least effect on the qtc and tp-e intervals, and therefore will be helpful in minimizing cardiovascular risks of deliberate hypotensive anesthesia.


Eligibility criteria:
inclusion criteria: 1. asa class 1 2. adults over the age of 20 3. patients requiring deliberate hypotensive anesthesia for orthognathic surgery exclusion criteria: 1. patient refusal 2. patients with arrhythmia 3. patients with cardiac anomalies or past history of cardiac surgery 4. patients with abnormal electrolyte levels 5. patients taking medications that are known to prolong qt intervals 6. patients with qtc intervals greater than 440ms 7. illiterate patients

Keywords: deliberate hypotension, qtc, tp-e, heart rate variability
clinical trial based on the use of mesenchymal stem cells from autologous bone marrow in patients with lumbar intervertebral degenerative disc disease

Conditions: Intervertebral Disc Disease

Summary: the purpose of this trial is to test the effectiveness of the use of a new therapeutic strategy in treating patients with degenerative disc disease lumbar intervertebral fusion with instrumented posterolateral autologous mesenchymal stem cells and arranged in a calcium phosphate ceramic (conduit tm).


Eligibility criteria:
inclusion criteria: clinical * box symptomatic (back pain and / or root) of lumbar degenerative disc disease monosegmental. * discopathy refractory to conservative treatment (drugs, physical therapy.) * evolution greater than or equal to 6 months. radiological * discopathy radiation. disc space narrowing, osteophytes, abnormal mobility, etc * nmr: grades iv and v of pfirman. exclusion criteria: * rejection of surgical treatment. * systemic inflammatory disease (spondylitis, rheumatoid arthritis etc), tumor or infection. * immunosuppressive treatment. * congenital or acquired anatomical abnormality that prevents the surgical procedure. * neuropsychiatric pathology, drug addiction, psychosis, severe personality disorder. * high surgical risk (asa\> iv), or contraindication to anesthesia.

Keywords: mesenchymal stem cells stem cells intervertebral disc disease
a study of intravenous mircera for the treatment of anemia in dialysis patients.

Conditions: Anemia

Summary: this single arm study will assess the efficacy and safety of intravenous mircera, administered with pre-filled syringes, for the treatment of anemia in patients with chronic kidney disease who are on dialysis, and who have previously received treatment with epoetin alfa or beta or darbepoetin alfa. patients will receive monthly intravenous injections of mircera, with the starting dose derived from the dose of epoetin alfa or beta or darbepoetin they were receiving in the week preceding study start. the anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.


Eligibility criteria:
inclusion criteria: * adult patients, \>=18 years of age; * chronic renal anemia; * longterm hemodialysis for \>=12 weeks before screening; * baseline hb between 10 and 13g/dl; * iv or sc maintenance epoetin alfa or beta or darbepoetin alfa therapy with same dosing interval for \>=4 weeks before screening. exclusion criteria: * acute or chronic bleeding within 8 weeks prior to screening; * transfusion of red blood cells within 8 weeks prior to screening; * poorly controlled hypertension necessitating interruption of erythropoetin treatment in previous 6 months; * previous treatment with mircera.
emotional processing in multiple sclerosis / clinically isolated syndrome: a neuropsychological fmri-study

Conditions: Multiple Sclerosis (MS); Clinically Isolated Syndrome (CIS)

Summary: the aim of this prospective non-interventional neuropsychological one visit study involving functional mri (fmri) is to ascertain emotional processing in patients with multiple sclerosis (ms) or clinically isolated syndrome (cis) compared to healthy control subjects. in different experiments, the modulation of cognitive and motor responses by visual emotional information and the ability to discriminate visual emotional stimuli will be tested using experimental behavioral paradigms. furthermore, functional connectivity and - using fmri - activations of brain regions known to be involved with emotional processing will be evaluated.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years and ≤ 85 years * right handed * for patients: diagnosis of cis or diagnosis of ms since ≤5 years exclusion criteria: * cognitive deficits as determined by a mmse score \< 25/30 * depression as determined by a hads-d score \> 7 * anxiety as determined by a hads-a score \> 7 * physical disabilities interfering with the study procedures or impacting outcome measures * clinically significant diseases within 7 days prior to the study evaluations * contraindications against cranial mri without contrast
study evaluating the effects of single oral doses of nsa-789 on auditory p50 suppression in schizophrenic patients

Conditions: Schizophrenia

Summary: the purpose of this study is to evaluate the effect of single doses of nsa-789 on the p50 component of the auditory evoked potentials and to assess the safety, tolerability and the concentration of nsa-789 in the blood, in nonsmoking patients with schizophrenia.


Eligibility criteria:
inclusion criteria: * women of nonchildbearing potential, or men, aged 18 to 55 years inclusive on study day 1. women of nonchildbearing potential may be included if they are either surgically sterile (hysterectomy and/or oophorectomy) or postmenopausal for â‰¥1 year (with a follicle-stimulating hormone \[fsh\] level of â‰¥38 miu/ml). women who are surgically sterile must provide documentation of the procedure by an operative report or ultrasound scan. sexually active men must agree to use a medically acceptable form of contraception during the study and continue it for 12 weeks after test article administration. * body mass index in the range of 18 to 32 kg/m2 and body weight â‰¥50 kg. * hemoglobin no lower than 0.4 g/dl, less than the lower limit of the normal range, and white blood cell count no lower than 0.5 103/mm3, less than the lower limit of the of the normal range at screening and day -1. hematocrit and absolute neutrophil count within normal range at screening and on day -1. exclusion criteria: * women of childbearing potential. * presence or history of any disorder that may prevent the successful completion of the study. * any unstable psychiatric condition, which may prevent the successful and safe completion of the study in the opinion of the investigator.
continuous positive airway pressure and cardiometabolic risk

Conditions: Sleep Disordered Breathing

Summary: the hypothesis for this study is that children with sleep disordered breathing will benefit from treatment with continuous positive airway pressure (cpap) or bi-level positive airway pressure (bipap) in terms of reduction in cardiovascular risk markers and insulin resistance. the cpap machine delivers a predetermined level of pressure. it releases a stream of compressed air through a hose to the nose mask and keeps the upper airway open under continuous air pressure. this air pressure prevents obstructive sleep apnea, which occurs as a result of narrowing of the airway due to the relaxation of upper respiratory tract muscles during sleep. this machine helps to increase the oxygen flow by keeping the airway open. the bipap machine delivers two levels of pressure. inspiratory positive airway pressure (ipap) is a high amount of pressure, applied when the patient inhales and a low expiratory positive airway pressure (epap) during exhalation.

obese children with moderate to severe sleep apnea will have baseline evaluation of markers of cardiometabolic risk and insulin resistance. subjects will then use either the cpap or bipap machine for 3 months and will return for another blood draw for measurement of the markers for cardiometabolic risk and insulin resistance.

Eligibility criteria:
inclusion criteria: 1. body mass index greater than 95th percentile for age and gender 2. moderate to severe obstructive sleep apnea (osa) (as defined by an apnea-hypopnea index (ahi) score of ≥5 events per hour). only patients who provide informed assent or consent and also have consent from a parent will be included. exclusion criteria: 1. predominant central sleep apnea 2. type 1 diabetes 3. type 2 diabetes 4. requires use of supplemental oxygen 5. active infection, cancer, or chronic inflammatory disorder 6. use of systemic steroids 7. simultaneous use of peroxisome proliferator-activated receptor (ppar)-alpha (e.g., gemfibrozil, fenofibrate) or ppar-gamma (e.g., rosiglitazone, pioglitazone)

Keywords: sleep disordered breathing cpap bipap cardiovascular risk markers
, "mucosal injury during nasotracheal intubation for dental procedures in children-does the tube design matter?"

Conditions: Epistaxis

Summary: comparison is made between standard nasotracheal tubes and a specially designed nasotracheal tube during nasotracheal intubation in children undergoing general anesthesia for dental surgery.

the parker flex-tip, midline-beveled nasotracheal tube theoretically slides past obstruction in the nasopharynx causing less mucosal damage than standard nasotracheal tubes. the investigators aim to test whether mucosal injury during nasotracheal intubation in children undergoing general anesthesia for dental procedures can thus be minimized taking into consideration adenoid size, and differences in nasopharyngeal diameter.

Eligibility criteria:
inclusion criteria: * children between the ages of 3-11, asa 1-3, presenting to wolfson children's hospital (wch) for dental procedures requiring general anesthesia with nasotracheal intubation. exclusion criteria: * asa \>3 * known bleeding disorders * recent or ongoing treatment with blood-thinning medicines * frequent epistaxis * active uri/congestion/rhinorrhea * craniofacial abnormalities prohibiting nti * known difficult airway * prior nasal surgery/trauma * allergies to any of the medicines used in this study.

Keywords: nasotracheal intubation adenoid size epistaxis nasopharyngeal mucosal injury
dose-dense therapy in aggressive lymphoma

Conditions: Lymphoma

Summary: to investigate if a dose-dense chemotherapy with weekly chemotherapy compared to standard treatment every 3 weeks results in better survival in aggressive non-hodgkin's lymphoma.

patients are randomized to receive dose-dense ceop/imvp-dexa chemotherapy or standard 3-weekly chop.

Eligibility criteria:
inclusion criteria: * 18 and 70 years of age * centrally reviewed, histologically proven diffuse large b-cell, anaplastic large-cell, or peripheral t-cell unspecified * measurable disease * all stages exclusion criteria: * lymphoblastic or burkitt histology * cns-disease * hiv-positive * pregnant or lactating women * pretreatment * other malignancy * concomitant diseases that forbid chemotherapy

Keywords: lymphoma aggressive chemotherapy dose-dense
ketamine and dexmedetomidine for delirium in joint arthroplasty

Conditions: Postoperative Delirium; Postoperative Cognitive Dysfunction

Summary: this prospective, randomized, double-blind, placebo-controlled clinical trial aims to evaluate the effects of intraoperative ketamine and dexmedetomidine on the incidence of postoperative delirium (pod) and postoperative cognitive dysfunction (pocd) in patients undergoing total joint arthroplasty. given the high incidence of neurocognitive complications in elderly patients following major orthopedic surgeries, neuroprotective strategies during anesthesia are of growing interest. both ketamine and dexmedetomidine have shown potential in reducing neuroinflammation and improving postoperative cognitive outcomes in previous studies. eighty adult patients (asa i-iii, aged 18-100) scheduled for elective total hip or knee arthroplasty under spinal anesthesia will be randomized into four groups: control (saline infusion), ketamine infusion, dexmedetomidine infusion, and combined ketamine + dexmedetomidine. cognitive assessments will be performed preoperatively and on postoperative days 2 and 15 using the mini mental state examination (mmse). delirium assessments will be conducted using the confusion assessment method (cam) postoperatively on days 1, 3, and 15. secondary outcomes include perioperative levels of cortisol, crp, and fibrinogen, as well as postoperative pain scores (vas) and analgesic consumption. the results are expected to clarify whether intraoperative administration of ketamine or dexmedetomidine can reduce the incidence of pod/pocd and improve postoperative recovery.


Eligibility criteria:
inclusion criteria: * scheduled for elective total joint arthroplasty (hip or knee) * asa physical status i-iii * age between 18 and 100 years * ability to provide informed consent and comply with cognitive assessments exclusion criteria: * pre-existing cognitive dysfunction or diagnosed neurodegenerative disease * hearing or language impairment interfering with mmse/cam evaluation * known allergy to ketamine or dexmedetomidine * significant cardiac arrhythmia (e.g., supraventricular tachycardia, 2nd or 3rd degree av block) * renal insufficiency (gfr \<30 ml/min/1.73 m²) * severe hepatic dysfunction
neural circuit mechanism of inflammatory bowel disease combined with depression

Conditions: Inflammatory Bowel Diseases

Summary: the goal of this observational study is to understand the effects of gut microbiota dysbiosis treatment in patients with inflammatory bowel disease (ibd) combined with depression. the main question it aims to answer is: does fecal microbiota transplantation (fmt) improve depression symptoms in ibd patients by altering gaba levels in the medial prefrontal cortex? participants already undergoing fecal microbiota transplantation (fmt) as part of their regular medical care for ibd and comorbid depression will undergo regular assessments of gaba levels, gut microbiota, and depression symptoms for the duration of the study.

the high incidence of inflammatory bowel disease (ibd) combined with depression increases the risk of disease recurrence and treatment failure. previous research by our team has found a positive correlation between decreased levels of the inhibitory neurotransmitter γ-aminobutyric acid (gaba) in the medial prefrontal cortex of ibd patients and the severity of depression. however, the underlying pathological mechanisms remain unknown. prior studies have suggested that gaba regulates activity within neural circuits in the brain, and the levels of gaba in the brain are influenced by the gut microbiota. based on this premise, our study aims to treat gut microbiota dysbiosis in ibd patients with comorbid depression using fecal microbiota transplantation (fmt). our team will analyze the correlation between changes in gaba levels in the medial prefrontal cortex and gut microbiota using techniques such as metagenomics, metabolomics, and magnetic resonance spectroscopy imaging. additionally, resting-state functional magnetic resonance imaging (fmri) is used to perform dynamic causal modeling of the neural circuit in the brain to elucidate the regulatory mechanism of gaba level changes on these circuits. finally, the investigators will validate the research findings using a dextran sulfate sodium (dss)-induced colitis mouse model to explore the neurochemical mechanisms underlying ibd comorbid with depression. the results of this study will not only provide a deeper understanding of the regulatory role of changes in brain gaba levels on neural circuits but also offer a theoretical basis for the use of fecal microbiota transplantation in treating gut microbiota dysbiosis in ibd patients and prevent complications such as depression.

Eligibility criteria:
inclusion criteria: aged 18-65 years right-handed active disease (cdai score ≥150, mayo score \>2). exclusion criteria: previous brain surgery those with severe and unstable physical diseases those with contraindications for mri who cannot tolerate long-duration mri examinations.